Filtered By:
Procedure: Hemodialysis
Nutrition: Iron
This page shows you your search results in order of date.
Order by Relevance | Date
Total 236 results found since Jan 2013.
The treatment effects and cardiovascular events of high-dose intravenous iron for hemodialysis patients with renal anemia: A systematic review and meta-analysis
CONCLUSIONS: In current meta-analysis, the high-dose intravenous iron might show the superior effects on the ferritin, transferrin saturation percentage, and hemoglobin levels and needed dose of erythropoietin when compared to low-dose iron treatment.PMID:37282508 | DOI:10.1177/17423953231180453
Source: Chronic Illness - June 7, 2023 Category: General Medicine Authors: Shanbao Zhang Meng Ouyang Lei Liu Source Type: research
Pleotropic effects of hypoxia-inducible factor-prolyl hydroxylase domain inhibitors: are they clinically relevant?
Kidney Res Clin Pract. 2022 Nov 21. doi: 10.23876/j.krcp.22.118. Online ahead of print.ABSTRACTAnemia is common in patients with chronic kidney disease (CKD) and is mainly caused by insufficient production of erythropoietin from fibrotic kidney. Because anemia impairs quality of life and overall prognosis, recombinant human erythropoietin-related products (erythropoiesis-stimulating agents, ESAs) have been developed to increase hemoglobin level for decades. However, many safety concerns have been announced regarding the use of ESAs, including an increased occurrence of cardiovascular events, vascular access thrombosis, can...
Source: Cell Research - January 12, 2023 Category: Cytology Authors: Yu-Hsiang Chou Szu-Yu Pan Shuei-Liong Lin Source Type: research
Innovations th érapeutiques dans la prise en charge de l’anémie de la maladie rénale chronique Therapeutic innovations in the management of chronic kidney disease-associated anemia
Nephrol Ther. 2022 Dec;18(6S1):6S25-6S32. doi: 10.1016/S1769-7255(22)00650-2.ABSTRACTAnemia is a common complication of chronic kidney disease (CKD). The insufficient erythropoietin (EPO) production by the kidneys and iron deficiency are the main causes. Iron supplementation and the administration of recombinant EPO are the main treatment modalities. New iron formulations that can be administered orally, intravenously or directly via the dialysate have recently been developed to improve efficacy and tolerance. Ferric citrate administered orally can effectively corrects anemia in case of iron deficiency and in addition chel...
Source: Nephrologie and Therapeutique - December 30, 2022 Category: Urology & Nephrology Authors: Julien Aniort Clarisse Greze George Kosmadakis Source Type: research
